117 results
The main objective of this study is to determine the role of TSH in the generation of new T cells by thymopoiesis
To assess the prevalence of HIV, hepatitis C and B, and (related) risk behavior among hard drug users in care at Mondriaan carecentre for addiction in Heerlen.
To assess, in patients with systemic lupus erythematosus, the effect on disease activity of a regimen with myfortic® versus continuation of azathioprine.
To investigate the efficacy (and the toxicity) of Glivec in systemic sclerosis by examining clinical outcomes (clinical and laboratory findings).
Primary Objective The prevalence and incidence of (pre)malignant and inflammatory pathology in the gastrointestinal tract of patients with a primary antibodydeficiency (CVID, XLA, IgG subclasse deficiency and abnormal vaccinationrespons). Secondary…
This is a scientific research with the aim to investigate the bioavailability of a combination of the drugs TMC114 and TMC41629 . The three dosage forms, each only once ingested. In addition, even in this study the safety of the use and possible…
To find an explanation for the abnormal blood levels of efavirenz. With the main research question: Are variations in genetic markers, e.g. CYP2B6 (subtype *6, *7 and *18), for the metabolism of efavirenz, an explanation for the abnormal…
In this study we intend to give the label "deuterium" to individuals as heavy water, to determine the turnover parameters of diverse leukocyte populations in health (young adults, healthy seniors of 60 years and older, healthy individuals…
Objective of this study is to determine the turnover of leukocyte populations in health (young, old) and how this compares to situations in which the immune system is disturbed ((HIV-1 infection, HSCT, thymectomy).
To set up a cohort of HIV infected MSM who subsequently acquired HCV infection with a known date of HCV seroconversion to study:- determinants/risk factors for acquiring HCV in HIV infected MSM- the outcome of HCV treatment in this population- the…
To examine the transmission of HIV variants.Have 1 or more viruses been transmitted?To examine the course of HIV-infection. Are differences in the course of HIV infection with same type viruses caused by genetic hostfactors Course more unfavourable…
Hypothesis:- The height of the result of the MTB-specific assays is directly related to the number of MTB bacilli present. As a result, effective treatment of persons with LTBI will cause a decrease of the quantitative test result and finally a…
The objectives are:1. the effect of steady state concentrations of voriconazole and fluconazole on the steady-state pharmacokinetics of TMC125,2. the effect of steady-state concentrations of TMC125 on the steady-state pharmacokinetics of…
Primary: Dose finding for a twice daily regimen for PSZ as prophylactic treatment in children with CGD, based on the exposure to PSZ measured by PSZ trough levels.Secondary:To determine the tolerability of PSZ as prophylactic treatment in children…
1. To study the possible association between MBL-deficiency and the occurence and severity of infections in MBL-deficient CF patients.2. To study the possible association between MBL-deficiency and the severity of cystic fibrosis.3. To study the…
Study whether chloroquine as comedication results in a better respons on Hepatitis B vaccination in non-responder dialysis patients.
Immune regulation in Common Variable Immunodeficiency: the role of apoptosis and regulatory T cells.
To gain insight in the regulation of immune responses in patients with CVID
In vitro data indicate that raltegravir is not a substrate of UGT1A4 or UGT2B7, but there is no evidence that raltegravir itself does not influence metabolism of other agents mediated by either UGT1A4 or UGT2B7.
Primary :To investigate the safety and tolerability of ascending single oral doses of JTK-656 administered to healthy male subjectsSecondary:To determine the pharmacokinetics (PK) of ascending single oral doses of JTK-656 administered to healthy…
The primary objective of the trial is to demonstrate non-inferiority of treatment with TMC278 when administered as 75 mg q.d. compared to the control group (EFV) in regard to the proportion of virologic responders (plasma viral load < 50 HIV-…